{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:23:47Z","timestamp":1791501827741,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>B7-H3 targeted therapies are an upcoming promising treatment option for a variety of solid tumors. High levels of B7-H3 expression have only been reported for a few sarcoma subtypes in previous studies, but a systematic analysis in an untreated sarcoma cohort and across many different sarcoma subtypes has not yet been conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      One hundred thirty-three sarcoma samples of previously untreated patients from different sarcoma entities including soft tissue sarcoma (STS,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009103) and bone sarcoma (BS,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930) were collected from two sarcoma centers in South-West Germany. Samples were centrally immunohistochemically stained and assessed for membranous B7-H3 expression. For further analysis of B7-H3 expression, H-Scores were calculated. Baseline characteristics such as sex, age, histology, grading, staging as well as outcome data like treatments, event-free and overall survival were collected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>B7-H3 was found to be broadly expressed (97%) across all tested sarcoma subtypes, with only four samples (3%) without B7-H3 expression. 45% of all samples had low (H-Score 1-100), 33% intermediate (H-Score 101\u2013200) and 19% high (H-Score 201\u2013300) membranous B7-H3 expression. Highest expression was found in pleomorphic liposarcoma (median 202.5), osteosarcoma (median 175) and angiosarcoma (median 167.5), whereas expression was lowest in myxoid and well differentiated liposarcoma (medians 44.5 &amp; 62.5) and chondrosarcoma (median 60). H-Scores were found to significantly correlate positive with histological grading irrespective of histological sarcoma subtype. Pre-treatment B7-H3 H-Scores did predict event-free but not overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>B7-H3 is a promising treatment target in sarcomas as it is highly expressed particular in high grade bone and soft tissue sarcomas, such as pleomorphic liposarcomas and osteosarcomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16255-0","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:25:13Z","timestamp":1780734313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samples"],"prefix":"10.1186","volume":"26","author":[{"given":"Linus D.","family":"Kloker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rottscholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas S.","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bronsert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Braig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Benzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Zender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph K. W.","family":"Deinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"16255_CR1","doi-asserted-by":"publisher","first-page":"e2500377","DOI":"10.1200\/PO-25-00377","volume":"9","author":"A Juan Ribelles","year":"2025","unstructured":"Juan Ribelles A, et al. Recurrent and Refractory Ewing Sarcoma Phase I\/II Trials: Current Perspective From the Euro-Ewing Consortium. JCO Precis Oncol. 2025;9:e2500377. https:\/\/doi.org\/10.1200\/PO-25-00377.","journal-title":"JCO Precis Oncol"},{"key":"16255_CR2","doi-asserted-by":"publisher","unstructured":"Cai Q, Que Y, Zhang X. Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-010074.","DOI":"10.1136\/jitc-2024-010074"},{"key":"16255_CR3","doi-asserted-by":"publisher","unstructured":"Sergi CM, et al. Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials. Biomedicines. 2025;13. https:\/\/doi.org\/10.3390\/biomedicines13030664.","DOI":"10.3390\/biomedicines13030664"},{"key":"16255_CR4","doi-asserted-by":"publisher","first-page":"1149106","DOI":"10.3389\/fonc.2023.1149106","volume":"13","author":"K Lacuna","year":"2023","unstructured":"Lacuna K, Bose S, Ingham M, Schwartz G. Therapeutic advances in leiomyosarcoma. Front Oncol. 2023;13:1149106. https:\/\/doi.org\/10.3389\/fonc.2023.1149106.","journal-title":"Front Oncol"},{"key":"16255_CR5","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.esmoop.2023.101618","volume":"8","author":"JY Blay","year":"2023","unstructured":"Blay JY, et al. Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies. ESMO Open. 2023;8:101618. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101618.","journal-title":"ESMO Open"},{"key":"16255_CR6","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/eji.200839028","volume":"39","author":"J Leitner","year":"2009","unstructured":"Leitner J, et al. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 2009;39:1754\u201364. https:\/\/doi.org\/10.1002\/eji.200839028.","journal-title":"Eur J Immunol"},{"key":"16255_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molimm.2019.10.026","volume":"117","author":"Y Gao","year":"2020","unstructured":"Gao Y, et al. LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma. Mol Immunol. 2020;117:20\u20138. https:\/\/doi.org\/10.1016\/j.molimm.2019.10.026.","journal-title":"Mol Immunol"},{"key":"16255_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos F, et al. B7-H3: An Attractive Target for Antibody-based Immunotherapy. Clin Cancer Res. 2021;27:1227\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2584.","journal-title":"Clin Cancer Res"},{"key":"16255_CR9","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-08-4517","volume":"69","author":"H Xu","year":"2009","unstructured":"Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009;69:6275\u201381. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4517.","journal-title":"Cancer Res"},{"key":"16255_CR10","doi-asserted-by":"publisher","first-page":"108153","DOI":"10.1016\/j.intimp.2021.108153","volume":"101","author":"R Feng","year":"2021","unstructured":"Feng R, Chen Y, Liu Y, Zhou Q, Zhang W. The role of B7-H3 in tumors and its potential in clinical application. Int Immunopharmacol. 2021;101:108153. https:\/\/doi.org\/10.1016\/j.intimp.2021.108153.","journal-title":"Int Immunopharmacol"},{"key":"16255_CR11","doi-asserted-by":"publisher","first-page":"153303382094224","DOI":"10.1177\/1533033820942245","volume":"19","author":"X Yang","year":"2020","unstructured":"Yang X, Feng KX, Li H, Wang L, Xia H. MicroRNA-199a Inhibits Cell Proliferation, Migration, and Invasion and Activates AKT\/mTOR Signaling Pathway by Targeting B7-H3 in Cervical Cancer. Technol Cancer Res Treat. 2020;19:1533033820942245. https:\/\/doi.org\/10.1177\/1533033820942245.","journal-title":"Technol Cancer Res Treat"},{"key":"16255_CR12","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.bbrc.2018.12.055","volume":"508","author":"XW Zhu","year":"2019","unstructured":"Zhu XW, et al. MicroRNA-506 inhibits the proliferation and invasion of mantle cell lymphoma cells by targeting B7H3. Biochem Biophys Res Commun. 2019;508:1067\u201373. https:\/\/doi.org\/10.1016\/j.bbrc.2018.12.055.","journal-title":"Biochem Biophys Res Commun"},{"key":"16255_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bpa.12829","volume":"30","author":"RK Kanchan","year":"2020","unstructured":"Kanchan RK, et al. MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3). Brain Pathol. 2020;30:732\u201345. https:\/\/doi.org\/10.1111\/bpa.12829.","journal-title":"Brain Pathol"},{"key":"16255_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41419-022-04542-0","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, et al. LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7-H3 in head and neck squamous-cell carcinoma. Cell Death Dis. 2022;13:109. https:\/\/doi.org\/10.1038\/s41419-022-04542-0.","journal-title":"Cell Death Dis"},{"key":"16255_CR15","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/2767-9764.CRC-23-0546","volume":"4","author":"CD Miller","year":"2024","unstructured":"Miller CD, et al. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies. Cancer Res Commun. 2024;4:1369\u201379. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0546.","journal-title":"Cancer Res Commun"},{"key":"16255_CR16","doi-asserted-by":"publisher","first-page":"101934","DOI":"10.1016\/j.ctrv.2019.101934","volume":"82","author":"P Thanindratarn","year":"2020","unstructured":"Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z. Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. Cancer Treat Rev. 2020;82:101934. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101934.","journal-title":"Cancer Treat Rev"},{"key":"16255_CR17","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/2767-9764.CRC-25-0293","volume":"5","author":"KB DeSantes","year":"2025","unstructured":"DeSantes KB, et al. Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025;5:1574\u201383. https:\/\/doi.org\/10.1158\/2767-9764.CRC-25-0293. A Phase I, Open-Label.","journal-title":"Cancer Res Commun"},{"key":"16255_CR18","doi-asserted-by":"publisher","first-page":"1351901","DOI":"10.3389\/fonc.2024.1351901","volume":"14","author":"S Jung","year":"2024","unstructured":"Jung S, et al. Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3). Front Oncol. 2024;14:1351901. https:\/\/doi.org\/10.3389\/fonc.2024.1351901.","journal-title":"Front Oncol"},{"key":"16255_CR19","doi-asserted-by":"publisher","first-page":"1391954","DOI":"10.3389\/fimmu.2024.1391954","volume":"15","author":"SJ Holzmayer","year":"2024","unstructured":"Holzmayer SJ, Liebel K, Hagelstein I, Salih HR, Marklin M. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas. Front Immunol. 2024;15:1391954. https:\/\/doi.org\/10.3389\/fimmu.2024.1391954.","journal-title":"Front Immunol"},{"key":"16255_CR20","doi-asserted-by":"publisher","unstructured":"Lavoie RR, et al. Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13184528.","DOI":"10.3390\/cancers13184528"},{"key":"16255_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak NJ, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2:366\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0206.","journal-title":"Cancer Discov"},{"key":"16255_CR22","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1186\/s12885-024-13061-4","volume":"24","author":"MM Lynch","year":"2024","unstructured":"Lynch MM, et al. B7-H3 is widely expressed in soft tissue sarcomas. BMC Cancer. 2024;24:1336. https:\/\/doi.org\/10.1186\/s12885-024-13061-4.","journal-title":"BMC Cancer"},{"key":"16255_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.lungcan.2013.07.016","volume":"82","author":"J Mazieres","year":"2013","unstructured":"Mazieres J, et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer. 2013;82:231\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2013.07.016.","journal-title":"Lung Cancer"},{"key":"16255_CR24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.1997.15.1.350","volume":"15","author":"L Guillou","year":"1997","unstructured":"Guillou L, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350\u201362. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.350.","journal-title":"J Clin Oncol"},{"key":"16255_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/PAT.0000000000000048","volume":"46","author":"A Neuville","year":"2014","unstructured":"Neuville A, Chibon F, Coindre JM. Grading of soft tissue sarcomas: from histological to molecular assessment. Pathology. 2014;46:113\u201320. https:\/\/doi.org\/10.1097\/PAT.0000000000000048.","journal-title":"Pathology"},{"key":"16255_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PAP.0000000000000293","volume":"28","author":"JH Choi","year":"2021","unstructured":"Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv Anat Pathol. 2021;28:119\u201338. https:\/\/doi.org\/10.1097\/PAP.0000000000000293.","journal-title":"Adv Anat Pathol"},{"key":"16255_CR27","unstructured":"Brierley J, et al. TNM classification of malignant tumours. Ninth edition edn; Wiley, 2025."},{"key":"16255_CR28","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res. 2019;25:2560\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432.","journal-title":"Clin Cancer Res"},{"key":"16255_CR29","doi-asserted-by":"publisher","first-page":"e70689","DOI":"10.1371\/journal.pone.0070689","volume":"8","author":"L Wang","year":"2013","unstructured":"Wang L, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS ONE. 2013;8:e70689. https:\/\/doi.org\/10.1371\/journal.pone.0070689.","journal-title":"PLoS ONE"},{"key":"16255_CR30","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-20-4221","volume":"27","author":"NM Kendsersky","year":"2021","unstructured":"Kendsersky NM, et al. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clin Cancer Res. 2021;27:2938\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4221.","journal-title":"Clin Cancer Res"},{"key":"16255_CR31","doi-asserted-by":"publisher","first-page":"18802","DOI":"10.1038\/s41598-021-98322-z","volume":"11","author":"T Kanayama","year":"2021","unstructured":"Kanayama T, et al. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma. Sci Rep. 2021;11:18802. https:\/\/doi.org\/10.1038\/s41598-021-98322-z.","journal-title":"Sci Rep"},{"key":"16255_CR32","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/pros.24180","volume":"81","author":"CE Nunes-Xavier","year":"2021","unstructured":"Nunes-Xavier CE, et al. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. Prostate. 2021;81:838\u201348. https:\/\/doi.org\/10.1002\/pros.24180.","journal-title":"Prostate"},{"key":"16255_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13000-023-01320-0","volume":"18","author":"JH Lee","year":"2023","unstructured":"Lee JH, et al. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis. Diagn Pathol. 2023;18:36. https:\/\/doi.org\/10.1186\/s13000-023-01320-0.","journal-title":"Diagn Pathol"},{"key":"16255_CR34","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.2147\/OTT.S318082","volume":"14","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, et al. Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer. Onco Targets Ther. 2021;14:4275\u201383. https:\/\/doi.org\/10.2147\/OTT.S318082.","journal-title":"Onco Targets Ther"},{"key":"16255_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s10637-023-01353-8","volume":"41","author":"S Omori","year":"2023","unstructured":"Omori S, et al. Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments. Invest New Drugs. 2023;41:356\u201364. https:\/\/doi.org\/10.1007\/s10637-023-01353-8.","journal-title":"Invest New Drugs"},{"key":"16255_CR36","doi-asserted-by":"publisher","first-page":"11507","DOI":"10.1200\/JCO.2024.42.16_suppl.11507","volume":"42","author":"L Xie","year":"2024","unstructured":"Xie L, et al. ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. J Clin Oncol. 2024;42:11507\u201311507. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.11507.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16255-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16255-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16255-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:29:41Z","timestamp":1781069381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16255-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16255"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16255-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients, and the study was conducted according to the Declaration of Helsinki. The study was approved by the local Institutional Review Board (IRB) of the University of T\u00fcbingen (Ethics Committee of the Faculty of Medicine of the University of T\u00fcbingen, reference no. 241\/2024BO2) and the University of Freiburg (Ethics Committee of the Faculty of Medicine of the University of Freiburg, reference no. 21-1735). Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"740"}}